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The diagnosis and follow-up of patients with bladder cancer relies
heavily on the use of invasive procedures, most commonly
cystoscopy with biopsy. Malignant cells are shed into the bladder
but the use of urine cytology has well documented limitations in
the diagnosis and monitoring of bladder cancer most particularly
in relation to sensitivity (Maier et al, 1995). A number of strategies
have been adopted to enhance the diagnostic potential of urine
samples to lessen the reliance on invasive procedures. Some inves-
tigators have studied bladder-washing samples which have the
advantage over voided urine samples of increased cellularity
(Walther, 1992). Recently interest has developed in the use of
cancer-associated genetic abnormalities as markers for the
presence of malignancy in such samples (Sidransky et al, 1991;
Levesque et al, 1993; Fitzgerald et al, 1995).
p53 mutations are the most common acquired or somatic
genetic abnormalities in human malignant disease (Hollstein et al,
1991) and occur frequently in bladder cancer. Mutations are most
common in high-grade and invasive bladder tumours (Fujimoto et
al, 1992) with up to 40–60% of muscle-invasive tumours carrying
mutations (Sidransky et al, 1991; Fujimoto et al, 1992; Esrig et al,
1993). Most p53 mutations are missense point mutations and
approximately 80% are found in the evolutionarily highly
conserved and functionally important exons 5–8 of the gene
(Nigro et al, 1989; Hollstein et al, 1991).
Sidransky et al (1991) were the first to describe p53 mutations
in bladder cancer – mutations were identified in nine out of a
cohort of 16 bladder cancers. Additionally, mutation-specific
oligonucleotides were used to demonstrate the presence of muta-
tions in corresponding urine samples in three cases, and it was esti-
mated that 1–7% of cells in these urine samples harboured the
relevant mutation.
Because of their relative frequency in bladder cancer, p53 muta-
tions were chosen to explore further the diagnostic potential of
molecular markers in this disease. The current study investigated
whether p53 mutations could be identified and characterized in
bladder washing samples from patients with bladder cancer
without prior knowledge of the mutation being sought. Exons 5–8
of the p53 gene were screened for the presence of mutations using
single-strand conformational polymorphism (SSCP) analysis and
when available corresponding bladder tumour specimens were
subsequently studied in the same way. Samples with abnormal
SSCP patterns were subjected to direct sequencing.
The study was undertaken with the approval of the Lothian
Research Ethics Committee.
MATERIALS AND METHODS
Subjects
Thirty-one bladder-washing samples were collected from 27
patients with bladder cancer, bladder washings being collected
from four patients on two separate occasions. In each case a bladder
abnormality was seen at cystoscopy. On 29 occasions a bladder
tumour was present. In two patients with previously documented
bladder cancer the biopsy taken at the time of bladder washing was
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Hospital, Crewe Road, Edinburgh EH4 2XU, UKabnormal, showing in one case carcinoma in situ and in the other
case dysplastic urothelium. Fresh bladder tumour biopsy specimens
were collected on 23 occasions from 20 of the above patients at the
time of bladder washing sample collection. The clinicopathological
characteristics of the subjects are shown in Table 1.
Sample collection
Bladder-washing samples were collected at the time of cystoscopy,
prior to any tumour resection (Hermansen et al, 1988). Normal
saline (50–60 ml) was repeatedly (3–5 times) injected into and
aspirated from the bladder. The resultant retrieved fluid was split
between two sterile containers and centrifuged at 2000 rpm for
10 min. The cellular pellets were then stored in liquid nitrogen.
When available a sample of resected bladder tumour was immedi-
ately snap-frozen in liquid nitrogen.
DNA preparation
DNA was extracted from bladder-washing samples and both fresh
and paraffin-embedded bladder tumour specimens using the QIA
amp tissue kit (Qiagen UK Ltd) following the manufacturer’s
instructions.
PCR-SSCP
A  32P radiolabelled PCR-SSCP assay was established based on the
method of Orita et al (1989). Four pairs of intronic primers were
designed to amplify the whole of each of exons 5–8 of the p53
gene. Primer sequences, product size and primer annealing
temperatures are shown in Table 2.
PCR
PCR reactions were performed in a 20 ml volume containing 1 ml
DNA (approx 100 ng) as template, 2 ml 10´ reaction buffer
(Promega, UK), 2 ml 2 mM dNTPs, magnesium chloride 1 mM,
0.2 ml of each of a primer pair (200 ng ml–1), 1.5 units PIC/Taq DNA
polymerase (ICRF Central Services, London, UK),
0.074 MBq  a32P dCTP (Amersham, UK), made up with distilled
water. All reactions contained a no template control, made up last,
to ensure the integrity of the reaction. PCR cyling was as follows:
94°C for 7 min, 35 cycles of 94°C for 1 min, primer annealing
temperature for 1 min (Table 2) and 72°C for 1 min; with a final
10 min at 72°C.
SSCP
Aliquots (2 ml) from the PCR reaction were mixed with 10 ml of
SSCP dye (95% formamide, 5 mM sodium hydroxide, 0.1%
bromophenol blue, 0.1% xylene cyanol), heated to 95°C for 5 min,
immediately chilled on ice and approximately 6 ml loaded per well
of a non-denaturing polyacrylamide gel. To increase the sensitivity
of the screen, all samples were run under three sets of gel condi-
tions (firstly 8% acrylamide, 2% bisacrylamide with 10% glycerol
run at 4°C and secondly 10% acrylamide, 1.3% bisacrylamide with
10% glycerol run at room temperature for all four exons studied;
finally either 8% acrylamide, 2% bisacrylamide with no glycerol
run at 4°C [exons 7 and 8] or 10% acrylamide, 1.3% bisacrylamide
with no glycerol run at 4°C [exons 5 and 6]). Gels were dried and
subjected to autoradiography. Reactions were only accepted if the
no template control yielded no product.
Direct DNA sequencing
DNA sequencing was performed using Sequenase Version 2.0
DNA sequencing kit (Amersham) as previously described
(Winship, 1989; Prosser et al, 1990). The sequencing template was
obtained from a non-radiolabelled PCR reaction of the relevant
exon of the sample of interest using either sample DNA or (if the
mutation was present as a small proportion of the sample)
abnormal single-stranded DNA eluted from an abnormal band
excised from a dried SSCP gel.
RESULTS
p53 mutations in bladder-washing specimens
Thirty-one bladder-washing samples from 27 patients were
studied. Exons 5–8 of the p53 gene were screened for the presence
of mutations. Five samples each from separate patients showed an
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Table 1 Clinicopathological characteristics of tumours
Histology
Transitional cell carcinoma 28
Squamous cell carcinoma 1
Mixed squamous TCC 2
Grade
Grade 1 (well differentiated) 4
Grade 2 (moderately differentiated) 4
Grade 3 (poorly differentiated) 21
Not applicable 2
Stage
pTa (superficial papillary) 8
pT1 (invades lamina propria) 5
pT2 (invades muscle) 14
pTx 2
CIS previous pT1 1
Dysplasia previous pTa 1
Table 2 PCR primers
Primer sequence Region amplified Product size Annealing temperature
Exon 5 Sense 5¢TGTGCCCTGACTTTCAACTC 42 bases upstream to 37 bases 263 base pairs 57°C
Antisense 5¢AACCAGCCCTGTCGTCTCTC Downstream of exon 5
Exon 6 Sense 5¢TGATTCCTCACTGATTGCTC 24 bases upstream to 20 bases 157 base pairs 53°C
Antisense 5¢ACCCCAGTTGCAAACCAGAC Downstream to exon 6
Exon 7 Sense 5¢AAGGCGCACTGGCCTCATCT 40 bases upstream to 30 bases 181 base pairs 59°C
Antisense 5¢CAGTGTGCAGGGTGGCAAGT Downstream of exon 7
Exon 8 Sense 5¢GGACCTGATTTCCTTACTGC 50 bases upstream to 54 bases 241 base pairs 57°C
Antisense 5¢GAGGCATAACTGCACCCTTG Downstream of exon 8138 HA Phillips et al
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abnormal SSCP pattern consistent with the presence of a mutation
(Figure 1). Of these mutations two were in exon 6, two in exon 7
and one in exon 8. Of the abnormalities found two were identifi-
able in all three sets of gel conditions used, two were seen in two
sets of conditions and one in only one, emphasizing the impor-
tance of using more than one set of gel to enhance sensitivity (data
not shown).
Correlation between mutation detection in surgical
biopsy/resection samples and bladder-washing samples
The concordance between the SSCP results obtained in bladder-
washing samples and those obtained from analysis in the same
manner of tumour tissue was evaluated. Twenty-three pairs of
bladder-washing and tumour samples (obtained at the same
cystoscopy) were available from a total of 20 patients, three
patients having pairs of samples taken on two different occasions.
The results are shown in Table 3. Concordant results (i.e. the pres-
ence or absence of an SSCP abnormality in both washing and
tumour) were found on 19/23 occasions (83%). In one patient two
pairs of samples showed an abnormality in the tumour samples but
in neither of the washings. In one case two pairs of samples were
again available and whilst both tumour specimens had an
abnormal SSCP only one of the two washings demonstrated it. In a
final patient an abnormality detected in tumour was again not
detected in the corresponding bladder-washing specimen (Figure
2). It is important to note that these results include three samples in
which the fresh bladder tumour specimen corresponding to SSCP
abnormal bladder-washing samples failed to demonstrate a muta-
tion. This was felt likely to represent poor tumour sampling and
therefore further DNA was extracted, this time from paraffin-
embedded tissue containing histologically confirmed tumour.
When these repeat samples were analysed they each demonstrated
the same SSCP abnormalities as the corresponding bladder-
washing samples. It remains possible therefore that in further
bladder tumour samples mutations were missed due to poor
sampling – paraffin-embedded tissue only being studied in the
three patients described above.
Confirmation of mutations detected by SSCP using
direct sequencing
The mutation present in 6 of the abnormal samples from four
patients were confirmed by direct sequencing (Table 4) and exam-
ples shown in Figure 3. It did not prove possible to characterize the
putative mutation in three samples with exon 7 abnormalities due
A1 8
A
A2 7
B
A3 3 0
C
A1 9
D
Figure 1 Autoradiographs of SSCP gels demonstrating abnormal migration patterns consistent with the presence of mutations in five out of 31 bladder
washing samples from patients with bladder cancer (abnormalities are indicated by arrows).(A) Exon 6: an abnormal extra band is seen in sample 18; (B) Exon
6: an abnormal extra band is seen in sample 27; (C) Exon 7: one abnormal extra band is seen in sample 3 and two extra bands in sample 30; (D) Exon 8: an
abnormal extra band is seen in sample 19. Lanes marked A show A2780 cell line normal controls (Brown et al, 1993)p53 mutations in bladder cancer 139
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to the technical failure to reamplify a double-stranded DNA
template for sequencing from single-stranded DNA eluted from
abnormal bands excised from dried SSCP gels. However, the
consistently reproducible nature of the SSCP pattern detected for
these samples strongly supports the presence of mutation rather
than SSCP artifact.
41T 41W A
Figure 2 Autoradiograph of SSCP gel illustrating the presence of an
abnormal extra band (®) indicating the presence of a mutation in the bladder
tumour sample from patient Z (41T) but not in the corresponding bladder
washing sample (41W) nor in the A2780 cell line normal control (A)
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Figure 3 Sequencing gels demonstrating: (A) a AGA-ACA mutation at
codon 280 (exon 8) in samples from patient N; (B) a GAC-AAC mutation at
codon 281 (exon 8) in samples from patient E
Table 4 Mutations confirmed by direct sequencing
Patient Sample(s) Exon Wild-type Mutation Codon
E 9 and 24 8 GAC(Asp) AAC(Asn) 281
M 18 and 26 6 TAG TAA Upstream splice site
N 19 8 AGA(Arg) ACA(Thr) 280
T 27 6 GAG(Glu) GCG(Ala) 224
Table 3 Correlation between SSCP abnormalities detected in bladder washing and tumour samples
Patient Sample Tumour pathology Tumour SSCP Bladder wash SSCP Correlate
A 3 G3pTC TCC Abnormal Exon 7 Abnormal Exon 7 Yes
B 6 G3pTC TCC Normal Abnormal Exon 7 Yes
C 7 G2pTa TCC Normal Normal Yes
D 8 G2pTa TCC Normal Normal Yes
E1 9 G3pT2 TCC/Sq Abnormal Exon 8 Normal No
E2 24 G3pT1 TCC/Sq Abnormal Exon 8 Normal No
G1 12 G3pT2 TCC Normal Normal Yes
G2 33 G3pT2 TCC Normal Normal Yes
H 13 G3pT2 TCC Normal Normal Yes
I 14 G3pT2 TCC Normal Normal Yes
J 15 G3pT2 TCC Normal Normal Yes
K 16 G3pT2 Sq Normal Normal Yes
M1 18 G3pT1 TCC Abnormal Exon 6 Abnormal Exon 6 Yes
M2 26 G3pTa TCC Abnormal Exon 6 Normal No
N 19 G3pT2 TCC Abnormal Exon 8 Abnormal Exon 8 Yes
O 20 G2pT1 TCC Normal Normal Yes
Q 22 G3pTa TCC Normal Normal Yes
S 25 G2pTx TCC Normal Normal Yes
T 27 G3pT1 TCC Abnormal Exon 6 Abnormal Exon 6 Yes
U 28 G1pTa TCC Normal Normal Yes
W 30 G3pT2 TCC Abnormal Exon 7 Abnormal Exon 7 Yes
Y 40 G1pTa TCC Normal Normal Yes
Z 41 G3pT2 TCC Abnormal Exon 7 Normal No
Patients from whom two pairs of samples were collected are indicated 1 and 2. Tumour samples in italics indicate those samples were an SSCP abnormality
was detected in paraffin-embedded tumour but not the original fresh tumour studied. TCC: Transitional carcinoma; Sq: Squamous cell carcinoma;
pT: pathological tumour stage; G: histological grade.140 HA Phillips et al
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DISCUSSION
Using standard methodologies it has been possible to detect and
characterize p53 mutations in a proportion of bladder-washing
samples from patients with bladder cancer. This detection did not
depend on prior knowledge of the mutation detected. Furthermore,
the presence of the same abnormalities could be demonstrated in
tumour biopsy or resection specimens.
However, there were four instances in which a mutation was
demonstrated in the tumour specimen but not in the corresponding
bladder-washing sample. Such false-negative bladder-washing
results are a concern and limit the clinical applicability of such an
assay using the methods employed in this study. As all patients
studied in the current investigation had visible cystoscopic abnor-
malities it seems likely that at least some tumour cells were shed into
the bladder-washing sample. The occurrence of false-negative
bladder-washing results is therefore most readily attributable to the
limited sensitivity of SSCP in detecting a mutation when the
mutation-carrying cells account for only a small proportion of the
sample. Sidransky et al (1991) estimated that only 1–7% of cells in
the urine samples of three patients with bladder cancer carried a
mutation. Such a level overlaps with the limits of sensitivity we have
defined for SSCP (Phillips et al, 1996) and readily explains the
occurrence of false-negative bladder washings. Whilst p53 immuno-
histochemical staining can show heterogeneous distribution within a
tumour (Sjogren et al, 1996) we are aware of no data from muta-
tional analyses describing an admixture of wild-type and mutant p53
within the same bladder cancer, and as such heterogeneity is an
unlikely cause of false-negative bladder washings.
Two further reports, both published whilst the current study was
in progress also establish that p53 mutations can be detected in
bladder-washing or urine samples using techniques that do not
require prior characterization of the mutation. First, Vet et al
(1996) demonstrated p53 abnormalities by SSCP of bladder
washings in 6/13 patients with superficial bladder cancer who
progressed to invasive disease but in only 1/13 who did not
progress. In the second study, Xu et al (1996) identified p53 muta-
tions in 13/28 patients with bladder cancer. Thirty urine samples
collected from eight patients whose tumours carried a mutation
were collected during 2 years of follow-up. Twenty-four of these
demonstrated the same mutation as the primary tumour, the six
negative results coinciding with normal appearing cystoscopies. In
six cases, despite a negative cystoscopy, mutation was detected in
the urine and this finding often heralded the subsequent develop-
ment of disease recurrence. In this study all mutation detection was
performed using direct sequencing, a method possibly less sensi-
tive than SSCP in a mixture of normal and malignant cells (Smith
et al, 1992; Wu et al, 1993). That these findings were achieved
despite using a technique of limited sensitivity emphasizes that the
detection of cancer-associated molecular abnormalities may offer
earlier detection of relapsed or recurrent disease than is possible
cystoscopically. Whilst the frequency of mutations in the H-ras
gene in bladder cancer is a contentious issue (Levesque et al,
1993). H-ras mutations can be detected in urine sediments of
patients with bladder cancer (Levesque et al, 1993; Fitzgerald et al,
1995) and have been shown to allow greater detection of low-
grade tumours than urine cytology (Fitzgerald et al, 1995).
A further promising approach to the molecular monitoring of
bladder cancer involves the detection of the same microsatellite
abnormalities present in bladder tumour samples in corresponding
urine samples (Mao et al, 1996). A sensitivity of detecting one
malignant cell in a background of 102–103 normal cells has been
reported (Mao et al, 1996) and it has been shown that the persis-
tence or reappearance of a previously detected abnormality
following treatment relates to subsequent disease recurrence
(Steiner et al, 1997). Collectively these data emphasize that the use
of molecular markers in material shed from bladder cancers bears
further study.
In conclusion, the current study demonstrates that the detection
and characterization of tumour suppressor gene mutations is
possible in bladder-washing specimens. It is appropriate to
consider the use of such methods for the study of the natural
history of bladder cancer as bladder washings are a method of
sampling the bladder epitheliums in its entirety. For clinical
applicability in disease-monitoring following the treatment of
bladder cancer sensitivity will need to be improved. Given the
clonal nature of most bladder cancer recurrences (Sidransky et al,
1992) the development of sensitive mutation specific assays for a
particular mutation characterized in an individual patient’s primary
tumour may be an appropriate avenue of further research and
prospective evaluation in the follow-up of bladder cancer. Whilst
such methods of molecular monitoring of disease are labour- and
resource-intensive, they may well become practically achievable
given the rapid advances in molecular biological technology and
could potentially lead to a reduction in the frequency of invasive
procedures.
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